Laser coagulation or laser photocoagulation surgery is used to treat a number of eye diseases and has become widely used in recent decades. During the procedure, a laser is used to finely cauterize ocular blood vessels to attempt to bring about various therapeutic benefits. The procedure is used mostly to close blood vessels in the eye, in certain kinds of diabetic retinopathy; it is no longer used in age-related macular degeneration in favor of anti-VEGF drugs.
Medical uses
Diabetic retinopathy
The American Academy of Ophthalmologypractice guidelines recommend laser coagulation for people who have both mild to moderate nonproliferative diabetic retinopathy and clinically significant macular edema outside the fovea; treatment with anti-VEGF drugs is better than laser coagulation for clinically significant macular edema in the fovea. For people with severe NPDR and no macular edema, the AAO recommends laser photocoagulation for the whole retina; when there is macular edema, the laser coagulation focused on major lesions is recommended. As of 2016, while there is preliminary evidence that anti-VEGF drugs may be useful for proliferative diabetic retinopathy, laser coagulation across the whole retina is still preferred in the AAO recommendations, as there is long-term follow up data for laser treatment but not for drug treatment.
Diabetic macular edema
Anti-VEGF drugs are potentially superior to laser coagulation for diabetic macular edema; some specialists are using the drugs over laser coagulation.
Macular degeneration
The American Academy of Ophthalmology practice guidelines do not recommend laser coagulation therapy for macular degeneration, but said that it may be useful in people with new blood vessels in the choroid outside of the fovea who don't respond to treatment with anti-VEGF drugs. Argon, krypton, dye and diode lasers have been used with varying levels of energy have been used to try to prevent age-related macular degeneration by eliminating drusen. A Cochrane review published in 2015 found that while laser treatment reduces drusen, there is no difference from placebo at 2 years with respect to preventing vision loss. A 2007 Cochrane review on found that laser photocoagulation of new blood vessels in the choroid outside of the fovea using blue-green argon, green argon, red krypton, or near-infrared diode is effective and economical method, but that the benefits are limited for vessels next to or below the fovea.
Laser coagulation has been used in people with sickle cell retinopathy. A 2015 Cochrane review found two clinical trials conducted in the 1980s using three approaches - one single-center trial employed sectoral scatter laser photocoagulation using an argon laser; and in the second, two-center trial focused on feeder vessel coagulation, one center used an argon laser and the other used a xenon arc laser. Based on weak evidence, it appears that laser coagulation may be effective in preventing visual loss and vitreous haemorrhage in this condition but that it does not have an effect on regression of proliferative sickle retinopathy or preventing the development of new vessel growth.
In the eye, side effects and complications of laser photocoagulation are not infrequent and include loss of vision, worsening visual acuity, reduced night vision, and hemorrhaging in the eye. In about 8% of cases can cause scarring which in turn can lead to permanent central vision loss.
History
German ophthalmologist, Gerhard Meyer-Schwickerath is widely credited with developing the predecessor of laser coagulation, photocoagulation. In 1946, he started conducted the first experiments on light coagulation. In 1949, he performed the first successful treatment of a retinal detachment with a light beam by with a self-constructed device on the roof of the ophthalmic clinic at the University of Hamburg-Eppendorf. Results of using laser coagulation to treat diabetic retinopathy were first published in 1954. Conventional macular focal and grid laser photocoagulation were established as the treatment of choice for diabetic macular edema in the Early Treatment Diabetic Retinopathy Study, which published in 1985.
